|
1
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512.
2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
de Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Parker C, Nilsson S, Heinrich D, Helle SI,
O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et
al: Alpha emitter radium-223 and survival in metastatic prostate
cancer. N Engl J Med. 369:213–223. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Humm JL, Sartor O, Parker C, Bruland OS
and Macklis R: Radium-223 in the treatment of osteoblastic
metastases: A critical clinical review. Int J Radiat Oncol Biol
Phys. 91:898–906. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dekempeneer Y, Keyaerts M, Krasniqi A,
Puttemans J, Muyldermans S, Lahoutte T, D'huyvetter M and Devoogdt
N: Targeted alpha therapy using short-lived alpha-particles and the
promise of nanobodies as targeting vehicle. Expert Opin Biol Ther.
16:1035–1047. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Saad F, Carles J, Gillessen S, Heidenreich
A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O,
et al: Radium-223 and concomitant therapies in patients with
metastatic castration-resistant prostate cancer: An international,
early access, open-label, single-arm phase 3b trial. Lancet Oncol.
17:1306–1316. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sartor O, Coleman RE, Nilsson S, Heinrich
D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S,
Wilhelm S, et al: An exploratory analysis of alkaline phosphatase,
lactate dehydrogenase, and prostate-specific antigen dynamics in
the phase 3 ALSYMPCA trial with radium-223. Ann Oncol.
28:1090–1097. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Naito M, Ukai R and Hashimoto K: Bone scan
index can be a useful biomarker of survival outcomes in patients
with metastatic castration-resistant prostate cancer treated with
radium-223. Cancer Rep (Hoboken). 2(e1203)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jarvis P, Ho A and Sundram F: Radium-223
therapy for metastatic castration-resistant prostate cancer:
Survival benefit when used earlier in the treatment pathway. Nucl
Med Commun. 42:332–336. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Oguma Y, Hosono M, Okajima K, Inoue E,
Nakamatsu K, Doi H, Matsuura T, Inada M, Uehara T, Wada Y, et al:
Investigation into the optimal strategy of radium-223 therapy for
metastatic castration-resistant prostate cancer. Radiation.
2:273–284. 2022.
|
|
13
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Energy Market Authority of Singapore: EMA
restricts use of prostate cancer medicine Xofigo, London, 2018.
https://www.ema.europa.eu/en/medicines/human/referrals/xofigo.
|
|
15
|
McKay RR, Jacobus S, Fiorillo M, Ledet EM,
Cotogna PM, Steinberger AE, Jacene HA, Sartor O and Taplin ME:
Radium-223 use in clinical practice and variables associated with
completion of therapy. Clin Genitourin Cancer. 15:e289–e298.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sasaki D, Hatakeyama S, Kawaguchi H,
Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama
Y, et al: Effects of six-cycle completion and earlier use of
radium-223 therapy on prognosis for metastatic castration-resistant
prostate cancer: A real-world multicenter retrospective study. Urol
Oncol. 40:64.e1–64.e8. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fizazi K, Massard C, Smith M, Rader M,
Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, et al:
Bone-related parameters are the main prognostic factors for overall
survival in men with bone metastases from castration-resistant
prostate cancer. Eur Urol. 68:42–50. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yadav K and Lewis RJ: Immortal time bias
in observational studies. JAMA. 325:686–687. 2021.PubMed/NCBI View Article : Google Scholar
|
